July 12, 2024 03:00 PM EDT

How SCOTUS' decision in Chevron could change the way the FDA regulates biopharma

Zachary Brennan

Senior Editor

The Supreme Court’s decision late last month to overrule a decades-old legal doctrine will have major ramifications for the FDA and the biopharma industry it …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

How SCOTUS' decision in Chevron could change the way the FDA regulates biopharma

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Gene editing startup Tome Biosciences to lay off almost all workers

CDER chief says 'standards have not changed,' explaining increase in CRLs for biologics

Researchers downplay study that found a link between semaglutide and mental health

Gene insertion startup Tome Biosciences stops lab work as CEO shifts focus to deal talks

Genmab makes two C-suite additions as COO leaves; James Sabry leads a revamped supporting cast at BioMarin

Oncology biotech Bicara unveils IPO pitch same day as Zenas

How SCO­TUS' de­ci­sion in Chevron could change the way the FDA reg­u­lates bio­phar­ma

Zachary Brennan

Senior Editor

Sign up to read this article for free.

more like this

Gene edit­ing start­up Tome Bio­sciences to lay off al­most all work­ers

CDER chief says 's­tan­dards have not changed,' ex­plain­ing in­crease in CRLs for bi­o­log­ics

Re­searchers down­play study that found a link be­tween semaglu­tide and men­tal health

Gene in­ser­tion start­up Tome Bio­sciences stops lab work as CEO shifts fo­cus to deal talks

Gen­mab makes two C-suite ad­di­tions as COO leaves; James Sabry leads a re­vamped sup­port­ing cast at Bio­Marin

On­col­o­gy biotech Bicara un­veils IPO pitch same day as Zenas

How SCOTUS' decision in Chevron could change the way the FDA regulates biopharma

Gene editing startup Tome Biosciences to lay off almost all workers

CDER chief says 'standards have not changed,' explaining increase in CRLs for biologics

Researchers downplay study that found a link between semaglutide and mental health

Gene insertion startup Tome Biosciences stops lab work as CEO shifts focus to deal talks

Genmab makes two C-suite additions as COO leaves; James Sabry leads a revamped supporting cast at BioMarin

Oncology biotech Bicara unveils IPO pitch same day as Zenas